CS
TXMD icon

Candriam SCA’s TherapeuticsMD TXMD Stock Holding History

Candriam SCA’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,000
Closed -$1.21M – 788
2017
Q4 		$1.21M Sell
4,000
-6,600
-62% -$1.84M 0.02% 557
2017
Q3 		$2.8M Buy
10,600
+1,000
+10% +$289K 0.05% 384
2017
Q2 		$2.53M Buy
9,600
+3,000
+45% +$751K 0.05% 417
2017
Q1 		$2.38M Buy
6,600
+3,600
+120% +$1.11M 0.05% 409
2016
Q4 		$865K Buy
+3,000
New +$930K 0.02% 539

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA's TXMD Position: Q1 2018 in Review

Candriam SCA sold out of TherapeuticsMD (TXMD) in Q1 2018, closing a stake of 4,000 shares — an estimated $1.21M sold.

Candriam SCA first reported a position in TXMD in Q4 2016 and held it in 5 quarters. The position peaked at $2.8M in Q3 2017. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2018.

  • Candriam SCA reported no remaining TherapeuticsMD position as of Q1 2018 after selling out during the quarter.
  • Candriam SCA sold 4,000 TherapeuticsMD shares in Q1 2018, an estimated $1.21M.
  • Candriam SCA first reported a position in TherapeuticsMD in Q4 2016 and held it in 5 quarters.
  • Candriam SCA's TherapeuticsMD position peaked at $2.8M in Q3 2017.
  • 143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2018.

Based on Candriam SCA's 13F filing for Q1 2018, filed 9 May 2018.